FDA Approves First At-Home Starting Dose for Leqembi Alzheimer’s Treatment
RBC keeps Outperform at $242, Truist upgrades to Buy ($235 target).
NOTRELOAD AI
Rackspace Cuts 2026 Outlook and Announces $250M Raise to Accelerate AI Infrastructure Plans
BMO Capital calls Rackspace’s FY26 guidance cut a “meaningful reduction” but highlights improved visibility into its enterprise AI opportunity with AMD and Palantir.
Strong Medicare Outlook Drives Wells Fargo’s Bullish Upgrade on Humana
Analyst highlights improving Medicare margins and star ratings for stronger 2028 earnings.
BofA: It’s Too Early to Doubt AppLovin’s E-Commerce Advertising Push
Analyst highlights early-stage e-commerce ad growth and strong gaming outlook despite slight slowdown in merchant additions.
Oncolytics Biotech Advances REO 033 Trial with Promising Pelareorep Data in Hard-to-Treat Colorectal Cancer
New sites opening, patients enrolling, and FDA Type D meeting planned for August 2026.
Enlivex Secures FDA RMAT Designation for Allocetra in Knee Osteoarthritis
Phase IIb trial now underway with first U.S. patient dosed.